Venetoclax
Mixed Phenotype Acute Leukemia,T/Myeloid
Explore 3 assets in Mixed Phenotype Acute Leukemia,T/Myeloid →Floatz Rating
CCC53/100
Confidence
Indicative
Sponsor
yuejun Liu
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
38Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07012447CT.gov Venetoclax + Azacytidine for Newly Diagnosed ETP-like ALL and T-ALL With Myeloid Mutations | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Mixed Phenotype Acute Leukemia,T/Myeloid
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Venetoclax (this asset) | yuejun Liu | P2 | CCC · 53 |
| Decitabine | The First Affiliated Hospital of Soochow University | P3 | B |
| Dexasone | M.D. Anderson Cancer Center | P2 | B |
| Idarubicin | M.D. Anderson Cancer Center | P2 | B |
| Rituximab | M.D. Anderson Cancer Center | P2 | B |
| Vincristine Sulfate | M.D. Anderson Cancer Center | P2 | B |
| Cytarabine | yuejun Liu | P2 | B |
| (+)-Vincristine | M.D. Anderson Cancer Center | P2 | B |
| Sorafenib | M.D. Anderson Cancer Center | P2 | B |
+2 more in the Mixed Phenotype Acute Leukemia,T/Myeloid cohort
Other indications for Venetoclax
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | — | P4 | BB · 70 |
| Acute Myeloid Leukemia | — | P4 | BB · 69 |
| Chronic Myelomonocytic Leukemia | — | P2/3 | BB · 68 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Venetoclax in Mixed Phenotype Acute Leukemia,T/Myeloid. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/venetoclax-mixed-phenotype-acute-leukemiatmyeloid
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →